Summary (tl;dr)

A new highly mutated COVID-19 variant, BA.3.2, nicknamed "Cicada," is trending after recent reports from the CDC highlighted its global spread and potential to evade existing immunity from previous infections or vaccinations.

Essential Background

The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been marked by the continuous emergence of new variants. These variants often possess mutations that can alter transmissibility, severity, or the ability to evade immune responses, leading to a sustained need for global surveillance and periodic updates to vaccines. Previous dominant strains, such as JN.1 and LP.8.1, have shaped the public health landscape and guided vaccine compositions in recent years.

The Full Story

The Centers for Disease Control and Prevention (CDC) recently released a report in March 2026 detailing the emergence and international spread of the SARS-CoV-2 BA.3.2 variant, an Omicron sublineage. This variant, first identified in South Africa in November 2024, is notable for its significant number of mutations—approximately 70 to 75 in its spike protein—making it genetically distinct from earlier circulating variants like JN.1 and LP.8.1, which were targeted by 2025-2026 vaccines. It has now been detected in at least 23 countries worldwide.

In the United States, BA.3.2 was initially identified in June 2025 through traveler-based genomic surveillance at San Francisco International Airport in a person arriving from the Netherlands. Since then, detections have increased, with the variant found in patient clinical samples and 132-260 wastewater surveillance samples across 25 to 29 U.S. states by March 2026. While its prevalence in the U.S. currently remains low, accounting for about 0.55% of sequenced cases by mid-March 2026, it has shown higher prevalence in some European countries, reaching approximately 30% of sequenced samples in Denmark, Germany, and the Netherlands between November 2025 and January 2026.

Why It Matters

The BA.3.2 variant is generating concern due to its extensive mutations, which laboratory studies suggest could reduce the protective antibodies induced by prior infections or current vaccines. Although current clinical data have not yet indicated a clear signal of increased disease severity, the potential for immune evasion means that this variant could lead to new waves of infection and may necessitate updated vaccine formulations to maintain effectiveness. Public health authorities globally, including the CDC, are emphasizing the critical need for continued comprehensive genomic surveillance and monitoring through methods like wastewater and traveler-based screening to track its evolution and determine its full public health impact.

Geographic Location

• South Africa (first detected the BA.3.2 variant in November 2024)
• Mozambique (detection of BA.3.2 variant in March 2025)
• Netherlands (detection of BA.3.2 variant in April 2025; origin of traveler to US)
• Germany (detection of BA.3.2 variant in April 2025; high prevalence in samples between November 2025 and January 2026)
• Denmark (high prevalence of BA.3.2 variant in samples between November 2025 and January 2026)
• San Francisco International Airport, San Mateo County, California, United States (first U.S. detection via traveler-based genomic surveillance in June 2025)
• United States (detection of BA.3.2 variant in 25-29 states via wastewater and patient samples by March 2026)